Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,735
archived clinical trials in
Psoriasis

Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated:  12/31/1969
Aspen Dermatology, PLLC /ID# 38293
mi
from
Spanish Fork, UT
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated: 12/31/1969
Aspen Dermatology, PLLC /ID# 38293
mi
from
Spanish Fork, UT
Click here to add this to my saved trials
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated:  12/31/1969
Aspen Dermatology, PLLC /ID# 40183
mi
from
Spanish Fork, UT
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated: 12/31/1969
Aspen Dermatology, PLLC /ID# 40183
mi
from
Spanish Fork, UT
Click here to add this to my saved trials
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated:  12/31/1969
Aspen Dermatology, PLLC /ID# 40192
mi
from
Spanish Fork, UT
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated: 12/31/1969
Aspen Dermatology, PLLC /ID# 40192
mi
from
Spanish Fork, UT
Click here to add this to my saved trials
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated:  12/31/1969
Skin and Laser Surgery Center /ID# 40182
mi
from
Tysons Corner, VA
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated: 12/31/1969
Skin and Laser Surgery Center /ID# 40182
mi
from
Tysons Corner, VA
Click here to add this to my saved trials
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated:  12/31/1969
Dermatology & Laser Center NW /ID# 18324
mi
from
Bellingham, WA
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated: 12/31/1969
Dermatology & Laser Center NW /ID# 18324
mi
from
Bellingham, WA
Click here to add this to my saved trials
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated:  12/31/1969
Dermatology Associates /ID# 18328
mi
from
Seattle, WA
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated: 12/31/1969
Dermatology Associates /ID# 18328
mi
from
Seattle, WA
Click here to add this to my saved trials
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated:  12/31/1969
Dermatology Associates /ID# 19802
mi
from
Seattle, WA
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated: 12/31/1969
Dermatology Associates /ID# 19802
mi
from
Seattle, WA
Click here to add this to my saved trials
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated:  12/31/1969
Premier Clinical Research /ID# 28168
mi
from
Spokane, WA
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated: 12/31/1969
Premier Clinical Research /ID# 28168
mi
from
Spokane, WA
Click here to add this to my saved trials
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated:  12/31/1969
Komorous, Tacoma, WA /ID# 42007
mi
from
Tacoma, WA
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated: 12/31/1969
Komorous, Tacoma, WA /ID# 42007
mi
from
Tacoma, WA
Click here to add this to my saved trials
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated:  12/31/1969
Eastern Washington Dermatology /ID# 17542
mi
from
Walla Walla, WA
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated: 12/31/1969
Eastern Washington Dermatology /ID# 17542
mi
from
Walla Walla, WA
Click here to add this to my saved trials
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated:  12/31/1969
Saoud, Bridgeport, WV /ID# 17135
mi
from
Bridgeport, WV
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated: 12/31/1969
Saoud, Bridgeport, WV /ID# 17135
mi
from
Bridgeport, WV
Click here to add this to my saved trials
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated:  12/31/1969
Mountain State Clinical Resear /ID# 28146
mi
from
Clarksburg, WV
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated: 12/31/1969
Mountain State Clinical Resear /ID# 28146
mi
from
Clarksburg, WV
Click here to add this to my saved trials
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated:  12/31/1969
Hardy County Medical /ID# 28264
mi
from
Moorefield, WV
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated: 12/31/1969
Hardy County Medical /ID# 28264
mi
from
Moorefield, WV
Click here to add this to my saved trials
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated:  12/31/1969
Dermatology Assoc of WI /ID# 28142
mi
from
Appleton, WI
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated: 12/31/1969
Dermatology Assoc of WI /ID# 28142
mi
from
Appleton, WI
Click here to add this to my saved trials
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated:  12/31/1969
Great Lakes Dermatology /ID# 17061
mi
from
Pleasant Prairie, WI
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated: 12/31/1969
Great Lakes Dermatology /ID# 17061
mi
from
Pleasant Prairie, WI
Click here to add this to my saved trials
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated:  12/31/1969
Aylesworth, Rhinelander, WI /ID# 18322
mi
from
Rhinelander, WI
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated: 12/31/1969
Aylesworth, Rhinelander, WI /ID# 18322
mi
from
Rhinelander, WI
Click here to add this to my saved trials
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated:  12/31/1969
University Hospital St. Polten /ID# 22842
mi
from
St. Pölten,
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated: 12/31/1969
University Hospital St. Polten /ID# 22842
mi
from
St. Pölten,
Click here to add this to my saved trials
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated:  12/31/1969
David Fivenson, MD, PLC /ID# 20504
mi
from
Ann Arbor, MI
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated: 12/31/1969
David Fivenson, MD, PLC /ID# 20504
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated:  12/31/1969
Florida Acad Dermatology Ctr /ID# 24273
mi
from
Coral Gables, FL
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated: 12/31/1969
Florida Acad Dermatology Ctr /ID# 24273
mi
from
Coral Gables, FL
Click here to add this to my saved trials
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated:  12/31/1969
Hollywood Dermatology /ID# 17129
mi
from
Hollywood, FL
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated: 12/31/1969
Hollywood Dermatology /ID# 17129
mi
from
Hollywood, FL
Click here to add this to my saved trials
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated:  12/31/1969
Hollywood Dermatology /ID# 19771
mi
from
Hollywood, FL
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated: 12/31/1969
Hollywood Dermatology /ID# 19771
mi
from
Hollywood, FL
Click here to add this to my saved trials
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated:  12/31/1969
Water's Edge Dermatology /ID# 76114
mi
from
Stuart, FL
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated: 12/31/1969
Water's Edge Dermatology /ID# 76114
mi
from
Stuart, FL
Click here to add this to my saved trials
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated:  12/31/1969
Northwestern University Feinberg School of Medicine /ID# 28169
mi
from
Chicago, IL
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated: 12/31/1969
Northwestern University Feinberg School of Medicine /ID# 28169
mi
from
Chicago, IL
Click here to add this to my saved trials
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated:  12/31/1969
The Indiana Clinical Trials Center, PC /ID# 17153
mi
from
Plainfield, IN
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
Status: Enrolling
Updated: 12/31/1969
The Indiana Clinical Trials Center, PC /ID# 17153
mi
from
Plainfield, IN
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated:  12/31/1969
Arizona Research Center
mi
from
Phoenix, AZ
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated: 12/31/1969
Arizona Research Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated:  12/31/1969
Desert Medical Advances
mi
from
Palm Desert, CA
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated: 12/31/1969
Desert Medical Advances
mi
from
Palm Desert, CA
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated:  12/31/1969
North Florida Dermatology
mi
from
Jacksonville, FL
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated: 12/31/1969
North Florida Dermatology
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated:  12/31/1969
Tampa Medical Group, PA
mi
from
Tampa, FL
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated: 12/31/1969
Tampa Medical Group, PA
mi
from
Tampa, FL
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated:  12/31/1969
Arthritis and Rheumatology of Georgia
mi
from
Atlanta, GA
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated: 12/31/1969
Arthritis and Rheumatology of Georgia
mi
from
Atlanta, GA
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated:  12/31/1969
Sonora Clinical Research
mi
from
Boise, ID
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated: 12/31/1969
Sonora Clinical Research
mi
from
Boise, ID
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated:  12/31/1969
Rockford Orthopedic Associates, LTD
mi
from
Rockford, IL
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated: 12/31/1969
Rockford Orthopedic Associates, LTD
mi
from
Rockford, IL
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated:  12/31/1969
The Arthritis Center
mi
from
Springfield, IL
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated: 12/31/1969
The Arthritis Center
mi
from
Springfield, IL
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated:  12/31/1969
Justus Fiechtner, MD, PC
mi
from
Lansing, MI
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated: 12/31/1969
Justus Fiechtner, MD, PC
mi
from
Lansing, MI
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated:  12/31/1969
Physician's East
mi
from
Greenville, NC
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated: 12/31/1969
Physician's East
mi
from
Greenville, NC
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated:  12/31/1969
Austin Regional Clinic
mi
from
Austin, TX
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated: 12/31/1969
Austin Regional Clinic
mi
from
Austin, TX
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated:  12/31/1969
Houston Medical Research
mi
from
Houston, TX
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated: 12/31/1969
Houston Medical Research
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated:  12/31/1969
Center for Clinical Studies
mi
from
Houston, TX
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated: 12/31/1969
Center for Clinical Studies
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated:  12/31/1969
Luckster Enterprises
mi
from
San Antonio, TX
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated: 12/31/1969
Luckster Enterprises
mi
from
San Antonio, TX
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated:  12/31/1969
PharmaSeek
mi
from
Middleton, WI
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated: 12/31/1969
PharmaSeek
mi
from
Middleton, WI
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated:  12/31/1969
In Vivo Clinical Research
mi
from
Doral, FL
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated: 12/31/1969
In Vivo Clinical Research
mi
from
Doral, FL
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated:  12/31/1969
Centre For Rheumatology, Immun. And Arthritis
mi
from
Fort Lauderdale, FL
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated: 12/31/1969
Centre For Rheumatology, Immun. And Arthritis
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated:  12/31/1969
Atlanta Dermatology, Vein & Research Ctr
mi
from
Alpharetta, GA
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated: 12/31/1969
Atlanta Dermatology, Vein & Research Ctr
mi
from
Alpharetta, GA
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated:  12/31/1969
Indiana University
mi
from
Indianapolis, IN
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated: 12/31/1969
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated:  12/31/1969
Klein & Associates, MD, PA
mi
from
Cumberland, MD
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated: 12/31/1969
Klein & Associates, MD, PA
mi
from
Cumberland, MD
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated:  12/31/1969
Klein & Associates MD, PA.
mi
from
Hagerstown, MD
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated: 12/31/1969
Klein & Associates MD, PA.
mi
from
Hagerstown, MD
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated:  12/31/1969
Clinical Pharmacology Study Group
mi
from
Worcester, MA
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated: 12/31/1969
Clinical Pharmacology Study Group
mi
from
Worcester, MA
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated:  12/31/1969
Heartland Clinical Research, Inc.
mi
from
Omaha, NE
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated: 12/31/1969
Heartland Clinical Research, Inc.
mi
from
Omaha, NE
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated:  12/31/1969
Unifour Medical Research Associatets LLC
mi
from
Hickory, NC
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated: 12/31/1969
Unifour Medical Research Associatets LLC
mi
from
Hickory, NC
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated:  12/31/1969
Altoona Center for Clinical Research
mi
from
Duncansville, PA
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated: 12/31/1969
Altoona Center for Clinical Research
mi
from
Duncansville, PA
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated:  12/31/1969
Clinical Research Center of Reading, LLP
mi
from
West Reading, PA
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Status: Enrolling
Updated: 12/31/1969
Clinical Research Center of Reading, LLP
mi
from
West Reading, PA
Click here to add this to my saved trials